SPY420.86+5.94 1.43%
DIA338.78+5.82 1.75%
IXIC14,141.48+111.10 0.79%

Jefferies Upgrades Mirati Therapeutics to Buy, Lowers Price Target to $196

Jefferies analyst Maury Raycroft upgrades Mirati Therapeutics (NASDAQ:MRTX) from Hold to Buy and lowers the price target from $208 to $196.

05/10/2021 06:58
Jefferies analyst Maury Raycroft upgrades Mirati Therapeutics (NASDAQ:MRTX) from Hold to Buy and lowers the price target from $208 to $196.